{
    "nctId": "NCT01992952",
    "briefTitle": "Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer",
    "officialTitle": "A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor",
    "overallStatus": "UNKNOWN",
    "conditions": "Estrogen Receptor Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 149,
    "primaryOutcomeMeasure": "Phase 1b primary outcome measure: Maximum Tolerated Dose of AZD5363 in combination with fulvestrant",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal Women\n* Life expectancy 3 months\n* Histological confirmation of ER+ breast cancer\n* Clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection\n* Measurable or non-measurable disease\n* Adequate bone marrow, renal and hepatic function\n* Eastern Cooperative Oncology Group (ECOG) performance status \\< or equal to 2\n* Progressive disease whilst receiving an aromatase inhibitor (AI) for metastatic breast cancer (MBC)\n* Relapsed with metastatic disease whilst receiving an AI in adjuvant setting\n* Up to 3 prior lines of endocrine therapy for Advanced Breast Cancer\n* Up to 1 line of chemotherapy for Advanced Breast Cancer\n* Patient willing to donate archival tumour sample\n* Patient willing to donate baseline blood sample\n* Suitable for further endocrine therapy\n\nExclusion Criteria:\n\n* Previous treatment with fulvestrant or PI3K/mTOR(mammalian target of rapamycin )/Akt inhibitor therapy\n* Treatment with chemotherapy, immunotherapy or targeted, biologic or tumour embolisation within 21 days of study drug administration\n* Palliative radiotherapy within 7 days of study drug\n* Clinically significant abnormalities in glucose metabolism\n* Rapidly progressive visceral disease not suitable for further endocrine therapy\n* Known brain or leptomeningeal metastases\n* Any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol)\n* Concomitant medication unsuitable for combination with trial medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}